Trials
1 active
1 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “AMT-162, the investigational product (IP), is a nonreplicating, rep/cap-deleted, self-complementary Recombinant adeno-associated virus (rAAV) vector based on adeno-associated virus (AAV) serotype rh10 and contains complementary deoxyribonucleic acid (cDNA) encoding an artificial miRNA targeting the SOD1 gene.”In the company’s words, NCT06100276 on ClinicalTrials.gov
- Tested for
- Amyotrophic Lateral Sclerosis
- Main trialPhase 1/2
- “This is the study of AMT-162 in Participants with SOD1-ALS and is designed to evaluate the safety, tolerability, and exploratory efficacy of intrathecally administered gene therapy AMT-162. AMT-162-001 is a Phase 1/2, multi-center, single ascending dose study.”In the company’s words, NCT06100276 on ClinicalTrials.gov
Other drugs for Amyotrophic Lateral Sclerosis
Coming up1
- 30 Dec 2030Phase 1/2 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 16 NovCompletion date moved: 2026-09-30 to 2030-12-30 · ClinicalTrials.gov NCT06100276
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Active, not recruiting | 30 Dec 2030 | Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026